Skip to main content
SpringerLink
Log in

Immunotherapy in Endometrial Cancer: An Evolving Therapeutic Modality

  • Chapter
  • First Online:
Recent Advances in Endometrial Cancer

  • 372 Accesses

Abstract

Advanced endometrial carcinoma is a complex entity, with various histological, molecular, and biological patterns. The current therapeutic landscape is hazy, with some benefit of cytotoxic chemotherapy and/or hormonal therapy, at the best, in frontline setting only. Subsequent therapies are of little potential. The present role of immunotherapy in endometrial cancer is limited to only MSI-H patients. A few studies have tried to figure out better efficacy and safety of immune checkpoint inhibitors in certain molecular subsets. Further ongoing studies are trying to consolidate this evidence. This chapter highlights the current attempts in deciphering the molecular complexities of advanced endometrial cancer, in order to direct targeted therapies, in an individualized approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dowdy SC. Improving oncologic outcomes for women with endometrial cancer: realigning our sights. Gynecol Oncol. 2014;133:370–4.

    Article  Google Scholar 

  2. National Cancer Institute: SEER Stat Fact Sheets: Endometrial Cancer. http://seer.cancer.gov/statfacts/html/corp.html. Accessed 23 Aug 2015.

  3. National Comprehensive Cancer Network: Clinical Practice Guidelines for Uterine Neoplasms, Version2, 2019. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

  4. Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist. 2010;15:1026–33.

    Article  CAS  Google Scholar 

  5. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159–66. https://doi.org/10.1200/JCO.2004.07.184.

    Article  CAS  PubMed  Google Scholar 

  6. Miller DS, Filiaci G, Mannel R, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. LBA2. Presented at the 2012 Society of Gynecologic Oncology Annual Meeting, Austin, TX.

    Google Scholar 

  7. Longoria TC, Eskander RN. Immunotherapy in endometrial cancer—an evolving therapeutic paradigm. Gynecol Oncol Res Pract. 2015;2(1):11. https://doi.org/10.1186/s40661-015-0020-3

    Article  Google Scholar 

  8. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev. 2007;33(2):177–90. https://doi.org/10.1016/j.ctrv.2006.10.007.

    Article  CAS  PubMed  Google Scholar 

  9. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol. 2010;117(2):373–81. https://doi.org/10.1016/j.ygyno.2010.02.007.

    Article  CAS  PubMed  Google Scholar 

  10. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487.

    Article  Google Scholar 

  11. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015.

    Article  CAS  Google Scholar 

  12. Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011; 3:111ra120.

    Google Scholar 

  13. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852.

    Article  CAS  Google Scholar 

  14. Espinosa I, D’Angelo E, Palacios J, Prat J. Mixed and ambiguous endometrial carcinomas: a heterogenous group of tumors with different clinicopathologic and molecular genetic features. Am J Surg Pathol. 2016;40:972–81. https://doi.org/10.1097/pas.0000000000000640

    Article  Google Scholar 

  15. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  Google Scholar 

  16. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569–77.

    Article  CAS  Google Scholar 

  17. Moreno-Bueno G, Sánchez-Estévez C, Cassia R, Rodríguez-Perales S, Díaz-Uriarte R, Domínguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 2003;63:5697–702.

    CAS  PubMed  Google Scholar 

  18. Yalta T, Atay L, Atalay F, Caydere M, Gonultas M, Ustun H. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res. 2009;37:163–8.

    Article  CAS  Google Scholar 

  19. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

    Google Scholar 

  20. Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, Buonaguro L, Ciliberto G, Brauchli P, Pignata S. Tumor genotype and immune microenvironment in POLEultramutated and MSI-hypermutated Endometrial Cancers: new candidates for checkpoint blockade immunotherapy? Cancer Treat Rev. 2016;48:61–8. https://doi.org/10.1016/j.ctrv.2016.06.008

    Article  CAS  Google Scholar 

  21. Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem. 2014; 60:98–110. https://doi.org/10.1373/clinchem.2013.205740 .

  22. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67–73. https://doi.org/10.1038/nature12113 .

  23. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, Ochiel DO. Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol. 2010; 63(6):544–65. https://doi.org/10.1111/j.1600-0897.2010.00842.x.

  24. Vanderstraeten A, Tuyaerts S, Amant F. The immune system in the normal endometrium and implications for endometrial cancer development. J Reprod Immunol. 2015;109:7–16. https://doi.org/10.1016/j.jri.2014.12.006.

    Article  CAS  PubMed  Google Scholar 

  25. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7. https://doi.org/10.1038/nature06309

    Article  CAS  Google Scholar 

  26. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568–71. https://doi.org/10.1038/nature13954.

  27. Vanderstraeten A, Luyten C, Verbist G, et al. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63:545–57.

    Article  CAS  Google Scholar 

  28. T. Zhang, J. Xie, S. Arai, L. Wang, X. Shi, N. Shi, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a metaanalysis. Oncotarget. 2016; 7(45):73068–79.

    Google Scholar 

  29. Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S, Valabrega G. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget. 2017;8(52):90532–44. https://doi.org/10.18632/oncotarget.20042.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76(13):3767–72.

    Article  CAS  Google Scholar 

  31. de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 2009;114(1):105–10. https://doi.org/10.1016/j.ygyno.2009.03.022.

    Article  CAS  PubMed  Google Scholar 

  32. Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, et al. Immunofluorescence-detected infiltration of CD4 + FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. 2011;21(9):1628–34. https://doi.org/10.1097/IGC.0b013e31822c271f.

    Article  PubMed  Google Scholar 

  33. Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, et al. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol. 2017;145(3):446–52. https://doi.org/10.1016/j.ygyno.2017.03.006

    Article  CAS  Google Scholar 

  34. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Article  CAS  Google Scholar 

  35. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.

    Article  CAS  Google Scholar 

  36. Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41. https://doi.org/10.1200/JCO.2017.72.5952

    Article  CAS  Google Scholar 

  37. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126:2334–40. https://doi.org/10.1172/jci84940

    Article  Google Scholar 

  38. Makker V, Rasco DW, Dutcus EC, Stepan DE, Li D, Schmidt EW, Shumaker RC, Taylor MH. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. J Clin Oncol. 2017; 35:5598.

    Google Scholar 

  39. Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP. Regression of chemotherapy-resistant polymerase ε (POLE) ultra-mutated and MSH6 hypermutated endometrial tumors with nivolumab. Clin Cancer Res. 2016;22:5682–7.

    Article  CAS  Google Scholar 

  40. Fleming GF, Emens LA, Eder JP, Hamilton EP, Liu JF, Liu B, Molinero L, Fasso M, O’Hear C, Braiteh FS. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab in advanced/recurrent endometrial cancer (rEC). J Clin Oncol 2017; 35:5585.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gyne Oncology, Dharamshila Narayana Superspeciality Hospital, Delhi, India

    Satinder Kaur

  2. Narayana Superspeciality Hospital, Gurugram, Haryana, India

    H. S. Darling

Authors
  1. Satinder Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. S. Darling
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics & Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Obstetrics and Gynecology, UCMS & GTB Hospital, Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaur, S., Darling, H.S. (2020). Immunotherapy in Endometrial Cancer: An Evolving Therapeutic Modality. In: Mehta, S., Gupta, B. (eds) Recent Advances in Endometrial Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-15-5317-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-5317-2_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-5316-5

  • Online ISBN: 978-981-15-5317-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation